For example, incorporation of a membrane-bound IL-15 (mbIL-15) into CAR T-cell platforms has been shown to enhance the survival and function of T-cell therapies in a hostile tumor microenvironment (15, 18). The gene discussed is IL15; the disease is neoplasm.